NCT07259512 Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
| NCT ID | NCT07259512 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Evi Liliek Wulandari |
| Condition | Chronic Kidney Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2025-06-30 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Eligibility Criteria
Inclusion Criteria: * Female or Male with age \>18 years old * Patients with a diagnosis of CKD stage 3-5 non-dialysis with low ejection fraction heart failure (ejection fraction \< 40%) Exclusion Criteria: * Receiving hemodialysis therapy * History of intolerance to ACE inhibitors * Refractory hyperkalemia * Pregnancy * History of angioedema to ACE inhibitors * Receiving sacubitril-valsartan therapy * Receiving ARB therapy * Hypotension with blood pressure \<90/60, or patients in shock.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07259512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07259512 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07259512 currently recruiting?
Yes, NCT07259512 is actively recruiting participants. Contact the research team at evililiek@staff.uns.ac.id for enrollment information.
Where is the NCT07259512 trial being conducted?
This trial is being conducted at Kartasura, Indonesia.
Who is sponsoring the NCT07259512 clinical trial?
NCT07259512 is sponsored by Evi Liliek Wulandari. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.